Biocon signs pact with Mylan Inc
June 29th, 2009 - 12:54 pm ICT by IANSBangalore, June 29 (IANS) Indian biotechnology major Biocon Ltd Monday said it had signed an agreement with Mylan Inc. to develop, manufacture and supply generic biologic drugs globally.
Mylan Inc is a leading diversified generics and specialty pharmaceutical company.
“Through this partnership we hope to deliver high quality, affordable bio-generic antibodies and biologics, thereby addressing a critical need to lower spiralling healthcare costs in both the developed and emerging economies,” said Kiran Mazumdar Shaw, chairperson and managing director, Biocon Ltd.
As part of this agreement, both the companies will share development, capital and certain other costs to bring the products to the market.
- Karnataka to have five new bio-tech parks - Jul 11, 2011
- Pfizer snaps insulin marketing deal with Biocon - Mar 13, 2012
- Biocon net up 33 percent in first quarter - Jul 23, 2010
- Karnataka denies ban on clinical drug trials - May 04, 2011
- Biocon net marginally down in fiscal 2012 - Apr 27, 2012
- Biocon ties up with Pfizer to market biosimilars - Oct 18, 2010
- Biocon net up 59 percent in first quarter - Jul 23, 2009
- Biocon net profit up 20 percent in second quarter - Oct 22, 2010
- Biocon quarterly net profit up 25 percent - Apr 28, 2011
- Budget should incentivise biotech sector: Kiran Mazumdar-Shaw - Jul 05, 2009
- Weak rupee lowers Biocon net profit 80 percent in 2008-09 (Lead) - Apr 28, 2009
- Bangalore to host 10th edition of biotech expo June 2 - May 25, 2010
- Indian biotech sector rebounds on global recovery - Jun 02, 2010
- Biocon's Mazumdar-Shaw backs Bt brinjal cultivation - Jan 19, 2010
- Biocon, US firm to jointly make drug for diabetes - Sep 11, 2009
Tags: antibodies, bangalore, biocon ltd, biologics, biotechnology, chairperson, critical need, drugs, emerging economies, generics, healthcare costs, june 29, managing director, mylan, pact, partnership, pharmaceutical company, shaw, signs